Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-25-023486
Filing Date
2025-05-08
Accepted
2025-05-08 08:08:14
Documents
67
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q prme-20250331.htm   iXBRL 10-Q 846847
2 EX-31.1 q1202510-qex311.htm EX-31.1 12039
3 EX-31.2 q1202510-qex312.htm EX-31.2 12223
4 EX-32.1 q1202510-qex321.htm EX-32.1 7457
5 EX-32.2 q1202510-qex322.htm EX-32.2 7460
  Complete submission text file 0001628280-25-023486.txt   5356081

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT prme-20250331.xsd EX-101.SCH 39039
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT prme-20250331_cal.xml EX-101.CAL 64924
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT prme-20250331_def.xml EX-101.DEF 209455
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT prme-20250331_lab.xml EX-101.LAB 538437
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT prme-20250331_pre.xml EX-101.PRE 373628
69 EXTRACTED XBRL INSTANCE DOCUMENT prme-20250331_htm.xml XML 661264
Mailing Address 60 FIRST ST. CAMBRIDGE MA 02141
Business Address 60 FIRST ST. CAMBRIDGE MA 02141 617-465-0013
Prime Medicine, Inc. (Filer) CIK: 0001894562 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41536 | Film No.: 25923998
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)